Category «PHASE 3»

Omecamtiv mecarbil オメカムティブメカビル

It’s only fair to share… Omecamtiv mecarbil Molecular FormulaC20H24FN5O3 Average mass401.435 Da 4-[2-fluoro-3-[(6-methyl-3-pyridyl)carbamoylamino]benzyl]piperazine-1-carboxylic acid methyl ester AMG 423 AMG-423 CK1827452 CK-1827452; CK1827452 Cladribine [BAN] [INN] [JAN] [USAN] [Wiki] methyl 4-(2-fluoro-3-(3-(6-methylpyridin-3-yl)ureido)benzyl)piperazine-1-carboxylate 1-Piperazinecarboxylic acid, 4-[[2-fluoro-3-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenyl]methyl]-, methyl ester 2M19539ERK オメカムティブメカビル 873697-71-3 [RN] 9088 Methyl 4-(2-fluoro-3-{[(6-methyl-3-pyridinyl)carbamoyl]amino}benzyl)-1-piperazinecarboxylate NMR https://file.selleckchem.com/downloads/nmr/S262301-CK-1827452-NMR-Selleck.pdf In January 2019, Cytokinetics and licensees Amgen and Servier are developing oral modified- and immediate-release formulations of the cardiac …

SELETALISIB, селеталисиб , سيلستاليسيب , 司来利塞 ,

It’s only fair to share… SELETALISIB CAS 1362850-20-1 UCB-5857 , Plaque psoriasis,Sjoegren’s syndrome,Immunodeficiency disorders PHASE 3 UCB 23H14ClF3N6O , 482.85 Phosphatidylinositol 3 kinase delta (PI3Kδ) inhibitors 10023 1362850-20-1 [RN] N-{(1R)-1-[8-Chlor-2-(1-oxido-3-pyridinyl)-3-chinolinyl]-2,2,2-trifluorethyl}pyrido[3,2-d]pyrimidin-4-amine N—{(R)-1-[8-Chloro-2-(pyridin-3-yl)quinolin-3-yl]-2,2,2-trifluoroethyl}N-(1-oxypyrido-[3,2-d]pyrimidin-4-yl)amine Pyrido[3,2-d]pyrimidin-4-amine, N-[(1R)-1-[8-chloro-2-(1-oxido-3-pyridinyl)-3-quinolinyl]-2,2,2-trifluoroethyl]- 3-{8-chloro-3-[(1R)-2,2,2-trifluoro-1-({pyrido[3,2-d]pyrimidin-4-yl}amino)ethyl]quinolin-2-yl}pyridin-1-ium-1-olate селеталисиб [Russian] [INN] سيلستاليسيب [Arabic] [INN] 司来利塞 [Chinese] [INN] N-[(1R)-1-[8-chloro-2-(1-oxidopyridin-1-ium-3-yl)quinolin-3-yl]-2,2,2-trifluoroethyl]pyrido[3,2-d]pyrimidin-4-amine Seletalisib has been used in trials studying the treatment and basic science of Primary Sjogren’s Syndrome. Originator UCB Class Anti-inflammatories; Small molecules Mechanism …

PF-06650833

It’s only fair to share… PF-06650833 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide CAS 1817626-54-2 Chemical Formula: C18H20FN3O4 Molecular Weight: 361.3734 Originator Pfizer Class Anti-inflammatories; Antirheumatics Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors Phase II Rheumatoid arthritis Phase I Lupus vulgaris 01 Aug 2018 Pfizer completes a phase II trial in Rheumatoid arthritis (Treatment-experienced) in USA, Ukraine, Taiwan, Serbia, Russia, Romania, Poland, Mexico, South Korea, Georgia, Bosnia-Herzegovina, …

Golvatinib, ゴルバチニブ

It’s only fair to share… Golvatinib E-7050, cas 928037-13-2 1-N’-[2-fluoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1,1-Cyclopropanedicarboxamide, N-[2-fluoro-4-[[2-[[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]amino]-4-pyridinyl]oxy]phenyl]-N’-(4-fluorophenyl)- [ACD/Index Name] 516Z3YP58E 928037-13-2 [RN] 9565 E7050, ゴルバチニブ Molecular Formula: C33H37F2N7O4 Molecular Weight: 633.701 g/mol N’-[2-fluoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide UNII:516Z3YP58E Originator Eisai Co Ltd Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Piperazines; Piperidines; Pyridines; Small molecules Mechanism of Action Angiogenesis inhibitors; Proto oncogene protein c met inhibitors; Vascular endothelial growth factor receptor-2 antagonists Discontinued Gastric cancer; …

Savolitinib

It’s only fair to share… Savolitinib CAS 1313725-88-0, Molecular Formula, C17-H15-N9, Molecular Weight, 345.3685 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)- AZD-6094 AZD6094 HMPL-504 HMPL504 Savolitinib Savolitinib [INN] UNII-2A2DA6857R Volitinib HM 5016504 1H-1,2,3-Triazolo[4,5-b]pyrazine, 1-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)- 1-[(1S)-1-(Imidazo[1,2-a]pyridin-6-yl)ethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine [ 2A2DA6857R 9935 Phase III, AstraZeneca Hutchison China MediTech (Chi-Med), Cancer, kidney (renal cell carcinoma, papillary) A c-Met kinase inhibitor with antineoplastic activity. NCI: volitinib. An orally bioavailable inhibitor of …

Lumateperone

It’s only fair to share… Lumateperone Molecular FormulaC24H28FN3O Average mass393.497 Da 4-((6bR,10aS)-3-Methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 1-Butanone, 1-(4-fluorophenyl)-4-(2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)- 1-(4-fluorophenyl)-4-{4-methyl-1,4,12-triazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-5,7,9(16)-trien-12-yl}butan-1-one 313368-91-1 [RN] 70BSQ12069, Lumateperone, PHASE 3, ITI-007 4- methylbenzenesulfonate. SALT Molecular Formula: C31H36FN3O4S Molecular Weight: 565.704 g/mol (6bR,10aS)-8-[4-(4-Fluorophenyl)-4-oxobutyl]-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3‘,4’:4,5]pyrrolo[1,2,3-de]quinoxalin-8-ium 4-methylbenzenesulfonate 1187020-80-9 [RN] 1-Butanone, 1-(4-fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-, 4-methylbenzenesulfonate (1:1) ITI-007 tosylate JIE88N006O Lumateperone tosylate [USAN] UNII:JIE88N006O ITI 007 Originator Bristol-Myers Squibb Develope rIntra-Cellular Therapies Class Antidepressants; Antipsychotics; Pyrroles; Quinoxalines; Sleep disorder …

Nemorexant

It’s only fair to share… Nemorexant ACT-541468, UNII LMQ24G57E9 [(2S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone 1505484-82-1 [RN] LMQ24G57E9 Methanone, [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]- Originator Actelion Pharmaceuticals Developer Idorsia Pharmaceuticals Class Sleep disorder therapies Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists Phase III Insomnia 19 Oct 2018 Idorsia Pharmaceuticals plans a phase I trial for Liver disorders (Hepatic impairment) in November 2018 (PO) (NCT03713242) 09 Oct …

Molidustat

It’s only fair to share… Molidustat UNII-9JH486CZ13, cas no 1154028-82-6, MW: 314.3076 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Originator Bayer Schering Pharma Developer Bayer HealthCare Pharmaceuticals Class Antianaemics; Morpholines; Pyrazoles; Pyrazolones; Pyrimidines; Small molecules; Triazoles Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors Phase III Anaemia 24 Jun 2018 Biomarkers information updated 23 Jun 2018 Bayer initiates enrolment in the MIYABI HD-M phase III …

Revefenacin, ревефенацин , ريفيفيناسين , 瑞维那新 ,

It’s only fair to share… Revefenacin; 864750-70-9; TD-4208; UNII-G2AE2VE07O; G2AE2VE07O; TD-4208; GSK-1160724; 160724; GSK 1160724; TD-4028; YUPELRI Molecular Formula: C35H43N5O4 Molecular Weight: 597.76 g/mol [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate TD-4208 UNII:G2AE2VE07O ревефенацин [Russian] [INN] ريفيفيناسين [Arabic] [INN] 瑞维那新 [Chinese] [INN] Revefenacin is under investigation for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Originator Theravance Developer Theravance Biopharma Class Antiasthmatics; Biphenyl compounds; Carbamates; Piperidines Mechanism of Action Muscarinic receptor …

Vericiguat, ベルイシグアト

It’s only fair to share… Vericiguat BAY 102; BAY-1021189; MK-1242 1350653-20-1 Chemical Formula: C19H16F2N8O2 Molecular Weight: 426.3878 Vericiguat; 1350653-20-1; UNII-LV66ADM269; Methyl (4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate; BAY-1021189; LV66ADM269 Methyl (4,6-diamino-2-(5-fluoro-1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl(pyrimidin-5-yl)carbamate methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate Methyl{4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridi- n-3-yl]pyrimidin-5-yl}carbamate Originator Bayer HealthCare Pharmaceuticals Developer Bayer HealthCare Pharmaceuticals; Merck & Co Mechanism of Action Guanylate cyclase stimulants Phase III Chronic heart failure Phase I Coronary artery disease 28 May 2018 Phase …